You are here

Article Text

Article menu

Download PDFPDF

Spoken sessions
Clinical aspects of asthma
Free

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    S36 WRITING ABOUT EMOTIONAL EXPERIENCES TO IMPROVE LUNG FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ASTHMA: 3-MONTH FOLLOW-UP OF A RANDOMISED CONTROLLED TRIAL

    1CJ Jones, 1A Theadom, 1H Smith, 1M Hankins, 1R Bowskill, 2R Horne, 3AJ Frew. 1Brighton and Sussex Medical School, Brighton, UK, 2The School of Pharmacy, University of London, London, UK, 3Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

    Introduction: Stress has been associated with the exacerbation of asthma symptoms. Written emotional disclosure encourages people to write about their most stressful experiences facilitating cognitive and emotional processing. When conducted partly in a research laboratory, written emotional disclosure was found to yield a 12% increase in FEV1 percentage predicted in people with asthma. Given the link between stress and asthma, this trial was aimed at exploring the effectiveness of a 3-day written emotional disclosure intervention on lung function and quality of life for adults with asthma in a community setting.

    Methods: A randomised controlled trial was carried out on 138 adults with asthma aged between 18 and 45 years who were recruited through 32 general practices. Participants were randomly allocated to receive the emotional disclosure or the non-emotional control writing instructions. Participants completed the writing in their own home without researcher supervision for 20 minutes over three consecutive days. Assessments of lung function (FEV1 % predicted) using spirometry and questionnaires measuring quality of life, asthma symptoms, subjective asthma control and medication use were conducted at baseline, 1 and 3-month follow-up (see fig).

    Results: Baseline analysis showed a significantly higher proportion of smokers in the control condition but no differences in lung function. Controlling for smoking status, no significant findings for lung function, quality of life or asthma symptoms were found. At 3-month follow-up, participants in the intervention condition reported significantly better subjective control of their asthma (as defined by the asthma control test): odds ratio (OR) 3.01, 95% CL …

    View Full Text